Copenhagen, Denmark and Raleigh, North Carolina – 13 August 2015 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments, announces the expansion of its Raleigh, NC site to enable the relocation of its North American headquarters from Grayslake, Illinois.
One year on from its acquisition of the Raleigh plant from Fresenius Kabi, Xellia has taken on new premises adjacent to its dedicated lyophilized (free-dried) vial manufacturing facility.
The result is the combination of the Company's North American commercial function with the manufacturing facility into one location, forming the new headquarters for the territory. Staff based at the Grayslake site have begun a phased relocation.
Carl-Åke Carlsson, CEO Xellia said: "The US is a key market for Xellia and the expansion is part of our long term growth strategy and commitment to manufacturing in the US, for our North American customers. Consolidating our state-of-the-art production facility with our commercial headquarters will enable us to better serve our many customers – both with respect to proximity and working relationship. We are building a stronger, more connected US operation."
Xellia has over 100 years of pharmaceutical industry experience and specializes in difficult-to-manufacture and develop anti-infective products. The Company is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients (APIs) to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage form (FDF) of its drugs.
- ENDS -
Notes To Editors
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,000 people.
Xellia is a leading supplier of Vancomycin and Colistimethate Sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.
Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.
Further information about Xellia can be found at: www.xellia.com
Issued for and on behalf of Xellia by Instinctif Partners.
For more information please contact:
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Rich Zawadzki, General Manager,
Xellia Inc. North America
Tel: +1 201 606 3945
Instinctif Partners (media relations)
Melanie Toyne Sewell / Jen Lewis
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500
Email: [email protected]